In the study by Gou and Wu which demonstrated the frequencies of driver mutations in non‐small cell lung cancer in China,19 the mutation rates of EGFR were 48.4% (675/1795), 4.3% (9/208), and 28.2% (570/2021) in lung adenocarcinoma, squamous cell cancer (SCC) and NSCLC, respectively. This evidence concerns the gene EGFR and lung adenocarcinoma.